Proton therapy for prostate cancer is advantageous to imrt according to new study

October 25, 2017, Northwestern Memorial HealthCare

Proton therapy treatment for prostate cancer is associated with higher survival rates and decreased risk of complications compared to intensity-modulated radiation therapy (IMRT) according to a new study by researchers at the Northwestern Medicine Chicago Proton Center. The study is being presented at the 4th Annual Particle Therapy Co-Operative Group North-America (PTCOG-NA) Conference on October 25 in Chicago.

"This new evidence supports that proton therapy is at least as good as standard and may be significantly better in some areas, especially protecting normal tissue outside of the prostate," said the study's lead author William Hartsell, MD, medical director of the Northwestern Medicine Chicago Proton Center. "In addition, the evidence shows that proton therapy is advantageous for younger patients who we are most concerned about developing secondary cancers later in life."

Proton therapy uses protons - heavy, positively charged atomic particles - instead of the standard X-rays used in conventional radiation therapy. Protons deposit much of their energy, or dose, directly in the tumor and then stop, whereas conventional radiation continues to deposit the dose beyond the tumor.

Dr. Hartsell and colleagues reviewed the records of over 28,000 IMRT patients and 851 proton patients who received treatment from 2006-2012, using the Medicare and SEER (Surveillance, Epidemiology and End-Results Reporting) national databases. The proton patients were matched to IMRT patients in a 1:5 matching process using several parameters, including comorbidity index, cancer stage, tumor grade, adjuvant chemo/hormone therapy, age, zip code and ethnicity.

Using the matched patient cohort, the 5-year overall survival rate for proton therapy was 93.25% compared to 88.43% for IMRT. For the matched group of intermediate risk patients, the gap was slightly greater with a 5-year overall survival for proton therapy patients of 93.65% compared to 88.27% for IMRT.

The study also reviewed the incidence of complications and found significantly more patients with bladder, endocrine or "other" complications with IMRT compared to protons. In addition, there were greater numbers of patients with secondary malignancies with IMRT. 10.5% for IMRT compared to 6.1% for at 5 years.

"This study is a significant update on the efficacy of for prostate cancer. Many insurance companies are relying on outdated and incorrect data to determine coverage," said Dr. Hartsell.

Explore further: SBRT, proton beam therapy use increasing for prostate CA

Related Stories

SBRT, proton beam therapy use increasing for prostate CA

June 13, 2016
(HealthDay)—For men with prostate cancer, the use of stereotactic body radiotherapy (SBRT) and proton beam therapy increased from 2004 to 2011, according to a study published online May 25 in Cancer.

Proton therapy may be better option for elderly patients with esophageal cancer

October 25, 2017
A study led by Mayo Clinic researchers has found that proton beam therapy, in combination with chemotherapy, prior to surgery, may be a better option than a combination using traditional radiation therapy techniques with ...

Proton therapy has advantages over IMRT for advanced head and neck cancers

July 1, 2014
A new study by radiation oncologists at Mayo Clinic comparing the world's literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity ...

Despite hype, costly prostate cancer treatment offers little relief from side effects

December 13, 2012
Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation ...

Concurrent chemotherapy, proton therapy improves survival in patients with advanced lung cancer

July 20, 2017
For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according ...

Intensity Modulated Radiation Therapy optimal for localized prostate cancer

April 17, 2012
A treatment for localized prostate cancer known as Intensity Modulated Radiation Therapy (IMRT) is better than conventional conformal radiation therapy (CRT) for reducing certain side effects and preventing cancer recurrence, ...

Recommended for you

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.